Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTABLE-306: nimotuzumab plus concurrent chemoradiotherapy followed by maintenance for locally advanced cervical squamous cell carcinoma
CTR20240599Phase 3Active
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in Cervical Cancer (CC), cervical squamous cell carcinoma (CSCC), sponsored by Biotech Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on CTR20240599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240599.